EMA Authorised: Vosevi (sofosbuvir;velpatasvir;voxilaprevi) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA authorised Vosevi (sofosbuvir; velpatasvir; voxilaprevir) for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir (sofosbuvir)
• VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)
• Velpatasvir (velpatasvir)
• voxilaprevir (voxilaprevir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic. MAH: Gilead Sciences Ireland UC. Decision date: 07/08/2023